RIPK1 and metabolic dysfunction-associated steatotic liver disease: Those results suggested that in a conventional HFD model, which stimulates less severe NAFLD pathology than CD-HFD, UGDH-mediated RIPK1 suppression controls not only hepatocytes cell death and liver damage but also hepatic steatosis and inflammation.